Nucleic Acid Testing Market Report by Product Type, Technology, End User, and Region 2024-2032
세계의 핵산 검사 시장 규모는 2023년 30억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 51억 달러에 이를 것으로 평가되고, 예측 기간 동안 5.7%의 복합 연간 성장률(CAGR)을 나타낼 것으로 예측했습니다.
핵산 검사(NAT)란 환자의 혈액, 조직, 소변의 바이러스, 박테리아, 병원성 핵산을 스크리닝하는 분자 기술을 말합니다. 법의학 검사 및 수혈 감염, 유전병, 암 진단을 위해 실시됩니다. 핵산(NA) 추출, 표적 NA 증폭, 표적 앰플리콘 NA 검출에 의한 샘플 풀을 포함합니다. 검사에는 중합효소 연쇄반응(PCR), 쇄 치환 증폭(SDA), 리가아제 연쇄반응(LCR), 전사 매개 증폭(TMA), NA 서열별 증폭(NASBA) 공정을 실시하기 위한 키트 및 소모품 포함됩니다. NAT는 또한 눈에 보이는 증상이 없는 질병을 확인하고 거짓 반응성 해석을 해결하는데도 사용됩니다.
전 세계의적으로 감염성 세균과 바이러스성 질환의 유행이 증가하고 있는 것은 시장 성장을 가속하는 주요 요인 중 하나입니다. 게다가 진보된 진단 시스템에 대한 수요 증가도 시장 성장을 뒷받침하고 있습니다. 이에 따라 코로나바이러스병(COVID-19)의 발병도 항원을 검출하는 NAT 솔루션에 대한 수요를 높이고 있습니다. NAT는 감염의 효과적인 관리와 감염원의 정확한 식별에 널리 사용됩니다. 또한 신호 및 프로브 증폭 시스템을 포함한 새로운 생물학적 진단 기술의 개발과 같은 다양한 기술적 진보가 다른 성장 촉진요인으로 작용하고 있습니다. 이러한 혁신적인 기술은 질병의 조기 발견과 바이러스 감염 기간을 최소화하는 데 도움이 됩니다. 기타 요인으로는 광범위한 연구개발(R&D) 활동, 의료 인프라 개선 등이 있어 시장을 더욱 견인할 것으로 예상됩니다.
이 보고서에서 다루는 주요 질문
- 세계의 핵산 검사 시장은 지금까지 어떻게 추이하고 향후 어떻게 추이할 것인가?
- COVID-19는 세계의 핵산 검사 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은?
- 제품 유형별 시장 분석은?
- 기술별 시장 분석은?
- 최종 사용자별 시장 분석은?
- 업계의 밸류체인의 다양한 단계란?
- 업계의 주요 촉진요인과 도전은 무엇인가?
- 세계의 핵산 검사 시장의 구조와 주요 진출기업은?
- 업계 경쟁도는?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 핵산 검사 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역: 제품 유형별
제7장 시장 분석 : 기술별
- TMA-전사 개재 증폭
- PCR-중합효소 연쇄반응
- LCR-리가제 연쇄반응
- SDA-사슬 치환 증폭
- 기타
제8장 시장 분석 : 최종사용자별
제9장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Abbott Laboratories
- Agilent Technologies
- Becton, Dickinson and Company
- Bio-Rad Laboratories Inc.
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Illumina Inc.
- Merck KGaA
- Siemens Healthcare
- Tecan Group AG
- Thermo Fisher Scientific Inc.
BJH
The global nucleic acid testing market size reached US$ 3.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.
Nucleic acid testing (NAT) refers to a molecular technique for screening viruses, bacteria or pathogenic nucleic acid in the blood, tissue or urine of the patient. It is conducted for forensic testing and to diagnose transfusion-transmitted infections, genetic diseases and cancer. It involves sample pooling through nucleic acid (NA) extraction, target NA amplification and target amplicon NA detection. The testing involves kits and consumables for performing polymerase chain reaction (PCR), strand displacement amplification (SDA), ligase chain reaction (LCR), transcription-mediated amplification (TMA) and NA sequence-based amplification (NASBA) processes. NAT is also used for the identification of diseases with no visible symptoms and resolving false reactive interpretations.
The increasing prevalence of infectious bacterial and viral diseases across the globe represents one of the key factors driving the growth of the market. Furthermore, the increasing demand for advanced diagnostic systems is also driving the market growth. In line with this, the onset of the coronavirus disease (COVID-19) has also enhanced the demand for NAT solutions to detect the antigens. NAT is widely used for the effective management of communicable diseases and accurate identification of the infecting agent. Additionally, various technological advancements, such as the development of novel biological diagnostic techniques, including signal and probe amplification systems, are acting as other growth-inducing factors. These innovative techniques aid in the early detection of the disease and minimizing the infectious period of the virus. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global nucleic acid testing market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product type, technology and end user.
Breakup by Product Type:
Instruments
Reagents and Consumables
Breakup by Technology:
TMA- Transcription-mediated Amplification
PCR- Polymerase Chain Reaction
LCR- Ligase Chain Reaction
SDA- Strand Displacement Amplification
Others
Breakup by End User:
Hospitals and Clinics
Pathology Laboratories
Research Institutes
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Illumina Inc., Merck KGaA, Siemens Healthcare, Tecan Group AG and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report:
- How has the global nucleic acid testing market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global nucleic acid testing market?
- What are the key regional markets?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global nucleic acid testing market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Nucleic Acid Testing Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Instruments
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Reagents and Consumables
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Technology
- 7.1 TMA- Transcription-mediated Amplification
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 PCR- Polymerase Chain Reaction
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 LCR- Ligase Chain Reaction
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 SDA- Strand Displacement Amplification
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals and Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Pathology Laboratories
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Research Institutes
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Agilent Technologies
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Becton, Dickinson and Company
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Bio-Rad Laboratories Inc.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Danaher Corporation
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 F. Hoffmann-La Roche Ltd.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 SWOT Analysis
- 14.3.7 Illumina Inc.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Merck KGaA
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Siemens Healthcare
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.10 Tecan Group AG
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Thermo Fisher Scientific Inc.
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
